Bonus Biogroup Financials
| BONS Stock | ILS 10.80 0.10 0.92% |
Bonus |
Understanding current and past Bonus Biogroup Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bonus Biogroup's financial statements are interrelated, with each one affecting the others. For example, an increase in Bonus Biogroup's assets may result in an increase in income on the income statement.
Please note, the presentation of Bonus Biogroup's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bonus Biogroup's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bonus Biogroup's management manipulating its earnings.
Bonus Biogroup Stock Summary
Bonus Biogroup competes with Bezeq Israeli, El Al, Bank Leumi, Elbit Systems, and Tower Semiconductor. Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.| Foreign Associate | USA |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0004850116 |
| Business Address | Matam Advanced Technology |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bonusbiogroup.com |
| Phone | 972 7 320 67104 |
| Currency | ILS - Israeli Shekel |
You should never invest in Bonus Biogroup without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bonus Stock, because this is throwing your money away. Analyzing the key information contained in Bonus Biogroup's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bonus Biogroup Key Financial Ratios
Bonus Biogroup's financial ratios allow both analysts and investors to convert raw data from Bonus Biogroup's financial statements into concise, actionable information that can be used to evaluate the performance of Bonus Biogroup over time and compare it to other companies across industries.| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Number Of Employees | 13 | |||
| Beta | 1.4 | |||
| Z Score | 21.0 |
Bonus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bonus Biogroup's current stock value. Our valuation model uses many indicators to compare Bonus Biogroup value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bonus Biogroup competition to find correlations between indicators driving Bonus Biogroup's intrinsic value. More Info.Bonus Biogroup is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bonus Biogroup by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bonus Biogroup's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bonus Biogroup Systematic Risk
Bonus Biogroup's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bonus Biogroup volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Bonus Biogroup correlated with the market. If Beta is less than 0 Bonus Biogroup generally moves in the opposite direction as compared to the market. If Bonus Biogroup Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bonus Biogroup is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bonus Biogroup is generally in the same direction as the market. If Beta > 1 Bonus Biogroup moves generally in the same direction as, but more than the movement of the benchmark.
Bonus Biogroup December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bonus Biogroup help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bonus Biogroup. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bonus Biogroup based on widely used predictive technical indicators. In general, we focus on analyzing Bonus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bonus Biogroup's daily price indicators and compare them against related drivers.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 10.6 | |||
| Value At Risk | (3.97) | |||
| Potential Upside | 2.34 |
Complementary Tools for Bonus Stock analysis
When running Bonus Biogroup's price analysis, check to measure Bonus Biogroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus Biogroup is operating at the current time. Most of Bonus Biogroup's value examination focuses on studying past and present price action to predict the probability of Bonus Biogroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus Biogroup's price. Additionally, you may evaluate how the addition of Bonus Biogroup to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |